Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NTLA-2001 in ATTR amyloidosis
NCT04601051Phase 1Completed
- Sponsor
- Intellia Therapeutics
- Start
- Nov 2020
- Primary completion
- Sep 2025
- Modality
- Gene Silencing, CRISPR-Cas9, Lipid-based Nanoparticles
- Countries
- 4
01
Overview
Phase 1, open-label trial of nexiguran ziclumeran in transthyretin amyloidosis (ATTR) (5 arms), sponsored by Intellia Therapeutics. Primary endpoints: Treatment-Emergent Adverse Events at 730 days, Clinically Significant Clinical Laboratory Test Findings at 730 days and 11 more. Started Nov 2020; status: completed.
02
Drugs
nexiguran ziclumeran
03
Conditions
transthyretin amyloidosis (ATTR)
Beyond the preview
Go deeper on NCT04601051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04601051.